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LATS1, the large tumor suppressor 1 gene, encodes for a serine/threonine kinase protein
and is implicated in cell cycle progression. LATS1 is down-regulated in various human
cancers, such as breast cancer, and astrocytoma. Point mutations in LATS1 were reported
in human sarcomas. Additionally, loss of heterozygosity of LATS1 chromosomal region
predisposes to breast, ovarian, and cervical tumors. In the current study, we investigated
LATS1 genetic variations including single nucleotide polymorphisms (SNPs), in 28 Egyptian
patients with either urinary bladder or colon cancers. The LATS1 gene was amplified and
sequenced and the expression of LATS1 at the RNA level was assessed in 12 urinary
bladder cancer samples. We report, the identification of a total of 29 variants including
previously identified SNPs within LATS1 coding and non-coding sequences. A total of 18
variants were novel. Majority of the novel variants, 13, were mapped to intronic sequences
and un-translated regions of the gene. Four of the five novel variants located in the
coding region of the gene, represented missense mutations within the serine/threonine
kinase catalytic domain. Interestingly, LATS1 RNA steady state levels was lost in urinary
bladder cancerous tissue harboring four specific SNPs (16045 + 41736 + 34614 + 56177)
positioned in the 5’UTR, intron 6, and two silent mutations within exon 4 and exon 8,
respectively. This study identifies novel single-base-sequence alterations in the LATS1
gene. These newly identified variants could potentially be used as novel diagnostic or
prognostic tools in cancer.
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INTRODUCTION
The large tumor suppressor gene (LATS1), encodes for a ser-
ine/threonine protein kinase. It was first identified in Drosophila
melanogaster and later two mammalian homologs LATS1 and
LATS2 were identified (Yabuta et al., 2000, 2007). LATS1 shares
functional and structural similarities with LATS2. They are core
components of the Hippo signaling pathway that promotes tis-
sue growth and regulates cell proliferation. Mutations in the
Hippo signaling pathway have been associated with tissue over-
growth and development of tumors. In mammals, the activation
of the Hippo signaling inhibits cell proliferation through activa-
tion of the mammalian Ste20-like serine/threonine kinases 1 and
2 (MST1/2) that phosphorylates LATS1/2. Phosphorylated LATS1
in turn activates selected oncogenes such as yes-associated pro-
tein (YAP) or its paralog, the transcriptional co-activator with
Abbreviations: SNPs, single nucleotide polymorphisms; LATS, large tumor sup-
pressor gene; MST1/2, mammalian Ste20-like serine/threonine kinases 1 and 2;
YAP, yes-associated protein; BAX, Bcl-2-associated X; GWAS, genome-wide asso-
ciation study; Indels: insertions/deletions; UN, urinary bladder peritumoral tissue;
NC, peritumoral colon tissue; CC, colon cancer tissue; UC, urinary bladder cancer
tissue; CDC2, Cell Division Control; TF, transcription factor.
PDZ-bindingmotif (TAZ) (Hao et al., 2008). The phosphorylated
form of YAP gets sequestered in the cytoplasm resulting in sup-
pression of cell proliferation (Harvey and Tapon, 2007; Oka et al.,
2008).
LATS1 regulate cell cycle by inhibiting the activity of CDC2
kinases during mitosis. The N-terminus of the phosphorylated
LATS1 protein binds to CDC2 and reduces the activity of H1
histone kinase (Tao et al., 1999) leading to G2-M arrest (Xia
et al., 2002). The phosphorylated LATS1 was reported to inhibit
actin polymerization by binding to F-actin (Visser-Grieve et al.,
2011). In agreement with LATS1 role as a tumor suppressor,
its overexpression was observed to induce apoptosis by up-
regulating Bcl-2-associated X (BAX) protein and caspase-3 pro-
apoptotic proteins independent of P53 (Xia et al., 2002). The
tumor suppressor LATS1 is down regulated in various soft tis-
sue sarcomas (Hisaoka et al., 2002), and LATS1 down-regulation
was shown to be a poor prognostic factor in glioma cases (Ji
et al., 2012). Moreover, Lats1 knockout mice induced the forma-
tion of ovarian tumors and soft tissue sarcomas (St John et al.,
1999). Down-regulation of LATS1 expression due to its promoter
hyper-methylation was also observed in breast cancer, colorectal
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cancer and astrocytoma (Takahashi et al., 2005; Jiang et al., 2006;
Wierzbicki et al., 2013). Loss of heterozygosity in the LATS1 chro-
mosomal region was reported in ovarian tumors, breast tumors
and adenoid cystic carcinoma (Hansen et al., 2002; Takahashi
et al., 2005; Rutherford et al., 2006).
The human LATS1 gene is 57.3 Kb in length and is located
at chromosome 6q24–25.1 (Nishiyama et al., 1999). Large-
scale genome sequencing studies have identified various muta-
tions within this chromosomal region (Koed et al., 2005).
Chromosome 6 was shown to be a region that is frequently
subjected to allelic imbalances in bladder tumors (Koed et al.,
2005). High heterozygosity regions and nucleotide diversity were
observed on chromosome 6 and a total of 96,317 SNPs were
mapped to chromosome 6, with SNPs density about a sin-
gle SNP every 3.07 Kb (Sachidanandam et al., 2001). Particular
SNPs in this region were correlated with certain diseases. For
instance, a genome-wide association study (GWAS) of 19,091
cases with breast cancer and 20,606 controls has identified the
SNP rs9485372 in chromosome 6q25.1 near the LATS1 gene, and
associated it with risk to breast cancer (Long et al., 2012).
The genomic instability of the LATS1 chromosomal region
and the LATS1 down-regulation that was associated with var-
ious types of tumors intrigued a study of SNPs and inser-
tions/deletions (indels) within the LATS1 gene, as well as to assess
the effect of these single-base-sequence alterations on LATS1
expression in urinary bladder. Because of regional prevalence
of urinary bladder and colon cancer and the latter has been
previously reported to be associated with LATS1 promoter hyper-
methylation (Wierzbicki et al., 2013), we selected these particular
tissues. The aim of this study was achieved by scanning genomic
LATS1 for SNPs and indels in urinary bladder and colon tissues
from Egyptian patients. A total of 29 variants were identified,
including 18 novel variants and 11 SNPs previously identified
in the LATS1 gene (NCBI dbSNP Human Build 141, Released:
05/21/2014)1.
MATERIALS AND METHODS
PATIENTS AND TISSUE SAMPLES
Tissue samples were collected from 28 patients (25 males and 3
females). Informed consent to use tissue excised from patients
by the Pathology Department of Cairo University for the current
study was obtained from the 28 patients’ who voluntarily joined
the study. Data of the collected specimen were analyzed anony-
mously. The Institutional Review Board (IRB) of the National
Cancer Institute and the IRB of the American University in
Cairo approved all research protocols, followed in this study.
The patients mean age were 56.6 ± 12.8 (S.D) years. Based on
patients histopathology records, the 28 patients were categorized
into 4 groups; 3 normal urinary bladder tissues, 25 urinary blad-
der cancer tissues, 1 normal colon tissue and 3 Colon cancer
tissues. The normal tissues were excised from the tissue surround-
ing tumor tissue and were used as control. All the 28 samples
were used for SNPs detection and assessing microindels (≤10
nucleotides).
1Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda, MD:
National Center for Biotechnology Information, National Library of
Medicine. Available online at: http://www.ncbi.nlm.nih.gov/SNP/
RNA EXTRACTION, cDNA SYNTHESIS, AND PCR FOR CHECKING LATS1
EXPRESSION
Total RNA was extracted from tissues using Trizol reagent. DNase
digestions were done for all samples using RQ1 RNase-Free
DNase enzyme (Promega) to eliminate DNA contamination.
One-step cDNA were performed using Access RT-PCR system
(Promega) and GAPDH amplifications were performed to ensure
that the extracted RNA was sufficient for PCR amplification
following DNase digestion. This was followed by a two steps
cDNA, using RevertAid HMinus First Strand cDNA Synthesis Kit
(Fermentas), using random hexamer primers.
PCR was performed and the RNA steady state levels of
LATS1 were normalized to GAPDH. Forward and reverse
PCR primers were LATS1 Forward primer within exon
1, 5′- GCCTGGTGTTAAGGGGAGAG-3′, and reverse primer
within exon 2, 5′- CAAGTCTTGAAGCATTTGTGGA-3′, and
GAPDH Forward primer, 5′-TTAGCACCCCTGGCCAAGG-3′,
and reverse primer, 5′CTTACTCCTTGGAGGCCATG-3′ (Lin
et al., 2000). Expected PCR products sizes are LATS1 660 bp and
GAPDH 541 bp.
DNA EXTRACTION AND PCR AMPLIFICATION
Genomic DNA was extracted from all tissue samples using the
DNeasy Blood & Tissue Kit (QIAGEN). Seven sets of primers
were used to amplify the exons and the adjacent intronic region
(∼7000 bp). The primers utilized and the regions amplified are
illustrated in Figure 1 and supplemental Table 1. Multiple PCR
amplifications were done using FastStart High Fidelity PCR
System (5U/ aphic data μL) (ROCHE). The PCR products were
resolved on 1% agarose gels and purified using QIA quick Gel
Extraction Kit (QIAGEN).
RESTRICTION FRAGMENT LENGTH POLYMORPHISM (RFLP) FOR PCR
AMPLICONS
Prior to sequencing PCR products, RFLP was performed to con-
firm the LATS1 PCR amplified product. We used restriction
digestion enzymes that didn’t overlap with reported mutations
retrieved from the NCBI LATS1 SNPs database. TAQαI, EcoRI,
EcoRV, and EcoRI were used on PCR products of primer sets
1, 3, 5, and 6, respectively. DpnI was used with primer set 6
PCR amplicons that failed to digest with EcoRI, because DpnI
restriction enzyme cuts fully-adenomethylated DNA. Primer sets
2, 4, and 8 PCR amplicons were directly sequenced. Products
confirmed by RFLP (data not shown) were sequenced.
SEQUENCING
Sequencing was done using the BigDye Terminator v3.1 Cycle
Sequencing Kit fromApplied Biosystems. Each fragment from the
13 amplified portions of each sample (28 samples) was sequenced
at least twice (using the forward and reverse primers). The
sequences generated by the same primer pairs were assembled for
each of the four-histopathology patient group. This would allow
us to confirm single-base-sequence alterations in the sequence,
from the Forward and Reverse sequence.
DATA ANALYSIS, ANALYSIS SOFTWARE: POLYPHRED
The LATS1 sequences of each sample, in each of the 4 groups; 1-
Urinary Bladder Cancer, 2- normal peritumoral urinary Bladder,
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FIGURE 1 | Schematic representation of primers sets used to
amplify the LATS1 gene. 13 sets of primers were designed
(sequence details shown in Supplemental Table 1) to amplify and
sequence LATS1. Primer sets with an asterisk are the sets used for
amplification and sequencing of the LATS1 8 exon and the adjacent
5′ and 3′ intronic region. The sets without an asterisk are used in
the sequencing only. The primer sets used to assess LATS1
expression are presented with the red stars.
3- colon cancer, and 4- normal peritumoral colon were assem-
bled. Each group of sequences was aligned together and analyzed
using PolyPhred software program Version 6.15 Beta. Only SNPs
of rank 1 (97% for true positive SNP) and rank 2 (75% for true
positive SNP) were considered. All SNPs identified by PolyPhred
were compared to the NCBI LATS1 SNP database (Sherry et al.,
2001). SNP identified in our study and match the NCBI LATS1
SNPs (NCBI dbSNP Human Build 141, Released: 05/21/2014)
were considered an old SNP and those not matching the SNP
database were considered new variants.
Codon found to have SNPs were checked manually for the
amino acid it encodes and compared to the wild type version.
single-base-sequence alterations were checked for biological sig-
nificance to determine overlap with the Serine/ Threonine kinases
catalytic domain. Additionally small indels (insertions/ deletions)
of length 10 base pairs or less were analyzed using PolyPhred.
BIOINFORMATIC ANALYSIS
TRANSFAC Database Match tool (Kel et al., 2003; Matys et al.,
2006) was used to annotate the potential transcription factor (TF)
binding sites within the LATS1 gene using the positional weight
matrices database derived from the experimentally-proven
binding sites. Genome Trax™ (www.biobase-international.
com/genome-trax) analysis from BIOBASE Corporation was
used to map the SNPs/variants to the potential regulatory regions
in the LATS1 gene. Softberry-SNP-effect1 (Softberry Inc., www.
softberry.com) was used to predict the potential impact of the
SNPs/variants on the protein structure.
RESULTS
LATS1 AMPLIFICATION AND SEQUENCING
Peritumoral urinary bladder tissues, urinary bladder cancer tis-
sues, peritumoral colon tissue and colon cancer tissues were col-
lected from 28 patients suffering from urinary bladder cancer or
colon cancer. Table 1 summarizes patients’ clinical characteristics.
Table 1 | The clinical characteristics of patients in the study.
Variables Peritumoral Urinary Peritumoral Colon
urinary bladder colon cases cancer
bladder cases cancer cases
Total number 3 25 1 3
Male\female 3\0 23\2 1\0 2\1
Mean age (years) NA* 56.6 ± 12.8 NA* NA*
Smoking 2\1 8\15 NA* NA*
Bilharziasis 1\2 3\22 NA* 0\3
*NA, Not Available.
The genomic DNA from the tissues were extracted, fragments of
LATS1were amplified and sequenced followed by analysis of SNPs
and indels and microindels. Primers used to amplify the LATS1
gene are listed in supplemental Table 1 and presented in Figure 1.
RFLP was utilized to confirm the amplicons of exons 1, 3, 5, 6,
and 7 prior to sequencing (Supplemental Table 2). Alignment
of LATS1 amplicon/sequences to previously reported LATS1 gene
was performed and all LATS1 amplicon/sequences aligned to their
respective position.
IDENTIFICATION OF THE LATS1 VARIANTS INCLUDING SINGLE
NUCLEOTIDE POLYMORPHISMS (SNPs)
A total of 29 SNPs/variants were identified in the LATS1
gene. Among these 29 SNPs, 18 were novel variants and 11
SNPs were previously identified in the LATS1 gene in ear-
lier studies (Table 2). Seven SNPs/variants were identified in
the coding region of the LATS1 gene (Table 2). While, the
other 22 SNPs/variants were in the non-coding region of the
gene, including 5′UTR, introns and 3′UTR. Interestingly certain
SNPs/variants were associated with a particular type of tissue; two
variants were only found in the LATS1 gene of the urinary blad-
der cancer tissues, six peritumoral specific variants were found
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Table 2 | Summary of the SNPs/variants detected in the LATS1 gene.
Consensus The variant/SNP Position of the SNP/variant Novelty Corresponding Tissue samples
position genomic SNP/ variants type amino acid with the
position change SNP/variant
32 150039361 5′UTR (exon 1) G > C Previously
identified
− CC1, CC2, CC3, and NC1
100 150039293 5′UTR (exon 1) A > G Previously
identified
− NC1
245 150039148 5′UTR (exon 1) C > T Previously
identified
− UN1*, UN2, and CC1,
CC2***, CC3, NC1**
342 150039051 5′UTR (exon 1) T > A Novel − CC2
439 150038954 5′UTR (exon 1) T > A Novel − CC1, CC2, CC3
450 150038943 5′UTR (exon 1) T > A Novel − CC2
515 150038878 5′UTR (exon 1) T > A Novel − UN1, UN2, UN3
15908 150023485 Intron 1 C > A Novel − UN2
15943 150023450 Intron 1 T > A Novel − UN2, UN3
16045 150023348 5′UTR (exon 2) G > C Previously
identified
− UC1****, UC9, UC11,
UC13, UC15, UC19,
UC20, UC23, and NC1
16283 150023110 Exon 2, coding
region
G > A Novel Glu51Glu NC1
22891 150016502 Intron 2 T > C Previously
identified
− NC1
22899 150016494 Intron 2 G > C Novel − CC2, CC3, and NC1
34614 150004779 Exon 4, coding
region
T > C Previously
identified
Ser482Ser UC1, UC4, UC5, UC9,
UC11, UC15, UC16,
UC21, UC23, and UN1,
UN2
35366 150004027 Intron 4 T > G Previously
identified
− UC1, UC4, UC8, UC12,
UC13, UC14, UC15,
UC20, UC21, UC23, and
UN1
38335 150001058 Exon 5, coding
region
T > A Novel Leu849His
(Serine/Threonine
catalytic domain)
UN1
41346 149998047 Intron 6 G > A Novel − CC1, CC2, CC3
41625 149997768 Exon 6, coding
region
G > A Novel Arg900His
(Serine/Threonine
catalytic domain)
UC1, UC4, UC5, UC8,
UC9, UC12, UC16, UC17,
UC18, UC23, UC24
41736 149997657 Intron 6 A > G Previously
identified
− UC1, UC4, UC5, UC7,
UC8, UC9, UC10, UC11,
UC12, UC13, UC15,
UC16, UC17, UC20,
UC21, UC23, UC24, and
UN2, UN3
42029 149997364 Intron 6 T > A Novel − UC5, UC8, UC10, UC12,
UC13, UC15, UC21,
UC23, UC24
56152 149983241 Exon 8, coding
region
C > T Novel Ala1006Val
(Serine/Threonine
catalytic domain)
UN2, UN3
56164 149983229 Exon 8, coding
region
T > C Novel Phe1010Ser
(Serine/Threonine
catalytic domain)
UN2, UN3
56177 149983216 Exon 8, coding
region
C > T Previously
identified
Asp1014Asp UC1, UC8, UC9, UC11,
UC15, UC21, UC23, and
UN1, UN3, NC1
(Continued)
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Table 2 | Continued
Consensus The variant/SNP Position of the SNP/variant Novelty Corresponding Tissue samples
position genomic SNP/ variants type amino acid with the
position change SNP/variant
56976 149982417 Exon 8, 3′UTR T > C Previously
identified
− NC1
57142 149982251 Exon 8, 3′UTR A > C Previously
identified
− CC1, CC2, CC3, and NC1
57149 149982244 Exon 8, 3′UTR G > C Novel − CC1, CC2, CC3, and NC1
57154 149982239 Exon 8, 3′UTR A > C Novel − NC1
57155 149982238 Exon 8, 3′UTR T > A Novel − CC1, CC2, CC3, and NC1
57160 149982233 Exon 8, 3′UTR T > A Novel − NC1
*UN, peritumoral urinary bladder tissue; **NC, peritumoral colon tissue; ***CC, colon cancer tissue; ****UC, urinary bladder cancer tissue.
in the LATS1 of the peritumoral urinary bladder tissues, another
six peritumoral specific SNPs/variants were found only in the
peritumoral colon cancer tissues and four variants were identified
in the colon cancer tissues (Table 2). Other SNPs/variants were
not tissue-specific, and were common between different tissue
types. For instance, 4 SNPs were identified in the urinary blad-
der cancer as well as peritumoral urinary bladder tissues and 5
SNPs/variants were identified in the peritumoral and cancerous
colon tissues.
The seven SNPs/variants identified in the coding region of
LATS1, comprise 3 SNPs/variants encoding silent mutations and
4 variants encoding missense mutations (Table 2). The missense
variants result in alteration of 4 different amino acids within the
Serine/Threonine catalytic domain of the LATS1 protein. The
novel variant at consensus position 38335, within exon 5, was
identified only in a peritumoral urinary bladder tissue (UN1).
This variant resulted in the replacement of leucine amino acid
with a histidine amino acid, at amino acid position 849, within
the Serine/Threonine catalytic domain. On the other hand, the
novel variant at consensus position 41625, located at exon 6 of the
LATS1 gene, was only detected in urinary bladder cancer tissues.
This resulted in alteration of an arginine amino acid into histidine
at the amino acid position 900, located at the Serine/Threonine
catalytic domain of the LATS1 protein. The peritumoral urinary
bladder tissues showed another two novel variants at exon 8 that
resulted in two missense mutations within the LATS1 protein.
These Serine/Threonine catalytic domain variants mutates ala-
nine to valine at amino acid position 1006, and phenylalanine to
serine at amino acid position 1010 (Table 2).
The three SNPs/variants within the coding region that caused
silent mutations includes a novel variant found in the peritu-
moral colon tissue at consensus 16283 in exon 2 (G > A) and
encodes for glutamic acid (Table 2). The two other silent SNPs
include a previously identified SNP at exon 4, detected in uri-
nary bladder cancer and peritumoral urinary bladder tissues, and
a previously identified SNP at exon 8 detected in the cancerous,
peritumoral urinary bladder tissues as well as peritumoral colon
tissue. These single-base-sequence alterations at consensus 34614
in exon 4 (T> C) and consensus 56177 in exon 8 (C> T) encode
for serine and aspartic acid, respectively (Table 2).
Majority of the 22 SNPs/variants identified within the non-
coding region of the LATS1 gene were located in both the 5′
and 3′UTRs. There were 8 SNPs/variants detected within exon
1 and 2 that corresponds to the 5′ UTR region, 6 SNPs/variants
within the 3′UTR within exon 8 and 8 SNPs/variants within the
introns 1, 2, 4, and 6 of the LATS1 gene (Table 2). Among the
eight SNPs/variants at the 5′UTR, 3 newly identified variants were
only detected in the colon cancer tissues (Table 2). Of the eight
SNPs/variants identified in the intronic regions (Table 2), only
three SNPs were previously reported. Two SNPs located within
intron 1 of the LATS1 gene were only detected in the peritu-
moral urinary bladder tissues. Five new variants were found in
the 3′UTR region (exon 8) and were only detected in colon cancer
and peritumoral colon tissue groups suggesting that they could be
tissue specific.
SEQUENCE TRANSPOSITION WITHIN THE LATS1 GENE
Primer set 5P (shown in Supplemental Table 1), designed to align
to exon 4 at consensus position 34481–34965 on the genomic
DNA, aligned to intron 5 to intron 7 of the LATS1 gene in one
of the three examined colon cancer tissues. This suggests that in
this sample exon 4 of the LATS1 gene was shifted to a new posi-
tion between intron 5 to intron 7 of the LATS1 gene in this colon
cancer sample. Note that the remaining 25 urinary bladder cancer
tissues and two colon cancer tissues amplified the intended exonic
region.
THE EXPRESSION OF LATS1 GENE HARBORING DIFFERENT
SNPs/VARIANTS
To assess if the various SNPs/variants alter the expression of the
LATS1 gene, we examined the RNA steady state levels of LATS1 in
the different urinary bladder cancer tissues utilized in this study
(Figure 2). The LATS1 gene was differentially expressed in the
different tissues. A urinary bladder cancer tissue sample (UC13)
showed higher levels of the LATS1 expression compared with per-
itumoral tissue and urinary bladder cancer tissue without any
variation within the LATS1 gene (UC6) (Figure 2). Nevertheless,
LATS1 RNA steady state levels were not observed in 3 urinary
bladder cancer tissue samples (UC1, UC11, and UC15). The uri-
nary bladder tissue samples examined, comprises LATS1 gene
with different SNPs/variants, showed different levels of LATS1
gene expression.
A total of seven SNPs/variants were identified in the urinary
bladder cancerous tissues (Table 3). All of these SNPs/variants
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FIGURE 2 | LATS1 expressions analysis using PCR. LATS1 expression was
examined in urinary bladder cancer tissues (UC), peritumoral urinary bladder
(UN). UC6 did not contain any SNP in the LATS1 gene. UC7 showed SNP at
41736; UC14 harbors SNP at 35366; UC1 has SNPs/variants at 16045, 34614,
35366, 41625, 41736, and 56177; UC4 has SNPs/variants at 34614, 35366,
41625, and 41736; UC5 has SNPs/variants at 34614, 41625, 41736, and
42029; UC8 has SNPs/variants at 35366, 41625, 41736, 42029, and 56177;
UC11 has SNPs at 16045, 34614, 41736, and 56177; UC13 harbors
SNPs/variants at 16045, 35366, 41736, and 42029; UC 15 harbors
SNPs/variants at 16045, 34614, 35366, 41736, 42029, and 56177; UC 20
harbors SNPs at 16045, 35366, and 41736. UN3 harbors SNPs/variants at
515, 15943, 41736, 56177, 56152, and 56164. GAPDH was used as an
endogenous control. Generuler 1 Kb Plus DNA Ladder (Fermentas®) was
used as a size marker.
Table 3 | Summary of the SNPs/variants detected in the LATS1 of the urinary bladder cancerous tissues.
Samples No. of SNPs/variants within Position of LATS1
the LATS1 gene of this sample SNP/variant expression
UC2, UC3,
UC6, UC22,
UC25
No SNPs U6 showed +
LATS1
expression.
UC19 1 SNP 16045 NA
UC14 1 SNP 35366 +
UC18 1 variant 41625 NA**
UC7 1 SNP 41736 +*
UC10 2 SNPs/variants 41736 + 42029 NA
UC17 2 SNPs/variants 41625 + 41736 NA
UC20 3 SNPs 16045 + 35366 + 41736 +
UC16 3 SNPs/variants 34614 + 41625 + 41736 NA
UC24 3 SNPs/variants 41625 + 41736 + 42029 NA
UC13 4 SNPs/variants 16045 + 35366 + 41736 + 42029 + + +
UC11 4 SNPs 16045 + 34614 + 41736 + 56177 −***
UC4 4 SNPs/variants 34614 + 35366 + 41625 + 41736 +
UC5 4 SNPS/variants 34614 + 41625 + 41736 + 42029 +
UC12 4 SNPs/variants 35366 + 41625 + 41736 + 42029 NA
UC9 5 SNPs/variants 16045 + 34614 + 41625 + 41736 + 56177 NA
UC21 5 SNPs/variants 34614 + 35366 + 41736 + 42029 + 56177 NA
UC8 5 SNPs/variants 35366 + 41625 + 41736 + 42029 + 56177 ±
UC1 6 SNPs/variants 16045 + 34614 + 35366 + 41625 + 41736 + 56177 −
UC15 6 SNPs/variants 16045 + 34614 + 35366 + 41736 + 42029 + 56177 −
UC23 7 SNPs/variants 16045 + 34614 + 35366 + 41625 + 41736 + 42029 + 56177 NA
*+, Showed LATS1 mRNA expression.
**NA, Not Available.
***−, Did not show LATS1 mRNA expression.
The bold font indicates the position of four SNPs, when combined, were associated with eliminated steady state levels of LATS1 RNA.
have a representative sample that was examined for the LATS1
expression. The urinary bladder cancerous tissue (UC6), that did
not comprise any variation within the LATS1 gene, expressed
LATS1. Three urinary bladder cancerous tissues (UC1, 11, and
15) did not express the LATS1 gene. These three samples were the
only samples that contained the combination of four previously
identified SNPs at positions 16045, 34614, 41736, and 56177.
The SNPs at consensus position 16045 and 41736 are located
within the 5′UTR and intron 6, respectively. The other two SNPs
(positions 34614 and 56177) represented missense mutations
located at exon 4 and exon 8, respectively.
IDENTIFICATION OF THE POTENTIAL REGULATORY REGIONS WITHIN
THE LATS1 GENE
The differential expression of the LATS1 mRNA in the urinary
bladder cancer tissues that shared LATS1 SNPs/variants suggested
a role for the SNPs/variants (in non-coding regions) in LATS1
expression. In silico analysis of the LATS1 sequence using
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Transfac database identified TF binding including GEN_INI,
AP-2alphaA, ZNF263, p53, ZF5, CDP CR1, and Nanog, that
overlap with five SNPs/variants (5′UTR), located at positions
100, 342, 439, 450, and 16045 (Table 4). Using Genome Trax
to map the SNPs/variants to potential regulatory regions in
the LATS1 sequence revealed CpG_islands that overlap with
seven SNPs/variants (5′UTR) (Table 4). The position of other
non-coding SNPs/variants at intron-2, 4, and 6 as well as at
3′UTR overlap with potential binding sites for several TFs includ-
ing FAC1, GR, HNF-3beta, ardi5a, Zfp105, RBP-Jkappa, Xvent-1,
RREB-1, Sp1, RREB-1, GKLF, Churchill, GKLF, CPBP, SF-1,
Nanog, RUSH-1alpha, SOX10, and SRY (Table 4).
To predict the effect of the SNPs/variants, located at the
coding regions, on the LATS1 protein structure, we used
Softberry-SNP-effect in silico tool to assess the impact of amino-
acid alterations. Four missense mutations and a single silent
mutation were reported in the serine-threonine catalytic domain.
These five single-base-sequence alterations, which are Leu849His,
Arg900His, Ala1006Val, Phe1010Ser, and Asp1014Asp, were
predicted to produce a damaged protein. On the other hand, the
two silent mutations, Glu51Glu, and Ser482Ser, that are located
at LATS Conserved Domain-1 and LATS Conserved Domain-2,
respectively, were predicted to be tolerated sequences for the
protein.
DISCUSSION
The large tumor suppressor 1 (LATS1) is inactivated in vari-
ous tumor types encompassing soft tissue sarcomas, and ade-
noid cystic carcinoma, as well as, breast, lung, prostate and
esophageal cancers. The inactivation of the LATS1 could be ini-
tiated by allelic loss of heteozygosity, gene deletion, point muta-
tion or hyper-methylation of the promoter region. However,
Table 4 | The reported LATS1 SNPs/variants that were mapped to the TF-binding regions predicted by Transfac database (Kel et al., 2003;
Matys et al., 2006).
SNP/variant SNP/variant CpG_island TF type TFBS consensus Mutated
consensus position position sequence within LATS1 sequence
32 5′UTR (exon 1) CpG_island
100 5′UTR (exon 1) CpG_island GEN_INI (96) cccCAGTC cccCgGTC
245 5′UTR (exon 1) CpG_island
342 5′UTR (exon 1) CpG_island AP-2alphaA (336) acGGACTctggccgc acGGACactggccgc
439 5′UTR (exon 1) CpG_island ZNF263 (438) ctCCTCC caCCTCC
450 5′UTR (exon 1) CpG_island p53
ZF5
(446) gtgCTCGAgttggcggggcg
(441) ctccagtGCTCGag
gtgCaCGAgttggcggggcg
ctccagtGCaCGag
515 5′UTR (exon 1) CpG_island
15943 Intron 1 Myogenin (15942) CtgCTG CAgCTG
16045 5′UTR (exon 2) CDP CR1
Nanog
(16043) aggaTCATTt
(16043) aggaTCATTttc
agcaTCATTt
agcaTCATTttc
22891 Intron 2 HNF-3beta (22891) tacAAACAg cacAAACAg
22899 Intron 2 FAC1
GR
(22894) aaacAGAACattaa
(22897) cAGAACattaatatca
aaacAcAACattaa
cAcAACattaatatca
35366 Intron 4 ardi5a
Zfp105
(35362) tcAATATttattca
(35357) gtattTCAATatttatt
tcAAgATttattca
gtattTCAAGatttatt
41346 Intron 6 Xvent-1 (41344) cagAAAATaggct caaAAAATaggct
42029 Intron 6 SREBP
RBP-Jkappa
(42023) gaatTCtCACAaa
(42025) atTCTCAcaaa
gaatTCACACAaa
atTCACAcaaa
56976 Exon 8, 3’UTR SF-1
Nanog
RUSH-1alpha
FAC1
SOX10
SRY
(56966) ctcataaCCTTGtt
(56967) tcataacCTTGTttttggta
(56971) aacCTTGTtt
(56972) accttGTTTTtggt
(56973) cCTTGTt
(56975) TTGTTt
ctcataaCCTcGtt
tcataacCTcGTttttggta
aacCTcGTtt
acctcGTTTTtggt
cCTcGTt
TcGTTt
57142 Exon 8, 3’UTR RREB-1
Sp1
RREB-1
GKLF
(57137) cCCCCAccccccgc
(57137) cccCCACCcc
(57138) cCCCACcccccgcc
(57140) CCACCcc
cCCCCcccccccgccc
cCCcCCcc
cCCCcCcccccgcc
CCcCCcc
57149 Exon 8, 3’UTR Churchill
Sp1
GKLF
CPBP
(57144) cCCCCG
(57144) cccCCGCCcc
(57147) CCGCCcc
(57149) GCCCCat
cCCCCc
cccCCcCCcc
CCcCCcc
cCCCCat
Bold letters indicate locations of the variants.
The upper case letters indicate highly conserved core binding sequence of the TFs.
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LATS1 mutations and biological significance in cancers remain
unidentified. This study examines the genomic LATS1 region for
single-base-sequence alterations in urinary bladder and colon
cancer tissues.
We have therefore designed 13 primer sets to amplify and
sequence the genomic LATS1 fragments including the eight exons
of the LATS1 gene, the adjacent intronic region, the exon-intron
boundaries, the 5′UTR and the 3′UTR (Figure 1). This allowed us
to screen for single-base-sequence alterations that could disrupt
the regulatory regions, the alternative splicing sites or the coding
regions in urinary bladder and colon tumors. The sequenced 13
amplified fragments of the 28 tissue samples were assembled and
compared to the LATS1 sequence on the NCBI (NC_000006.1).
We detected 29 variants/SNPs within the LATS1 gene in urinary
bladder and colon tumors, including 18 novel variants and 11
previously identified SNPs (Table 2). Certain SNPs/variants were
specifically detected in either urinary bladder or colon tissues and
other were detected in both tissue types.
Among these 29 SNPs/variants, there were 22 SNPs/variants
within the non-coding region (introns and UTRs) and seven
SNPs/variants located within the coding region of the LATS1
gene including three silent and four missense SNPs/variants.
All the reported missense variants are located within the
Serine/Threonine catalytic domain of the LATS1 protein
(Table 2). These four missense variants altered four amino acids
at amino acid position L849H, R900H, at A1006V and at F1010S
within the Serine/Threonine catalytic domain at amino acid
position 708–1130 on the LATS1 protein (Table 2). The mis-
sense mutation L849H was also detected in stomach cancer
(data not shown). These variants are likely to influence the
activity of the tumor suppressor gene LATS1 through chang-
ing the amino acid sequence of its’ catalytic domain. Although
the functionality of the LATS1 protein with the genotyped
SNPs/variants remains unidentified, the results reveal an asso-
ciation of these missense variants with the peri-tumoral and
tumor tissues that may impact the tumor suppressor activity of
LATS1. The other three SNPs/variants at the exons region of
exon 2 (A/G), exon 4 (C/T), and exon 8 (T/C) were silent and
did not alter the amino acid sequence of the encoded LATS1
protein.
We identified 22 SNPs/variants at the LATS1 non-coding
region including eight at the 5′UTR, six at the 3′UTR, and eight
at intronic regions. We scanned the intron-exon boundaries and
the possible SNPs/variants that may affect the alternative splic-
ing. However, none of the reported SNPs/variants were located at
splice sites. SNPs/variants at non-coding regions may alter LATS1
expression and affect the consequent post-transcription regula-
tion of the downstream genes. These SNPs/variants could have
interrupted an essential regulatory region of LATS1. Therefore,
we examined the RNA steady state levels of LATS1 in the
urinary bladder cancer tissues as representatives of different
SNPs/variants within the LATS1 gene. However, further studies
are desirable to analyze the consequences of the LATS1 non-
coding SNPs/variants on the LATS1 activity. That being said, in
the present study we observe an association of these SNPs/variants
with the differential expression of LATS1 in urinary bladder
tumors (Figure 2).
Moreover, a transposition of exon 4 into another position at
intron 5 to intron 7 of the LATS1 gene was observed in a colon
cancer tissue. This transposition within the LATS1 gene alters the
amino acid sequence of the Serine/Threonine catalytic domain
of LATS1 protein and may result in LATS1 inactivation in colon
cancer. The steady state levels of LATS1 RNA was examined using
PCR primers that cover the region from second half of exon 1 to
first half of exon 2, which allows detection of the two isoforms
of the LATS1 mRNA (Figure 1). One limitation in this study
is the lack of information on LATS1 expression levels for the
entire cohort. However, a total of seven different SNPs/variants
were reported in urinary bladder cancerous tissues and all of
them had representative tissue that was examined for the RNA
steady state levels of LATS1 (Table 3). A urinary bladder can-
cerous tissue (UC6) that did not encompass any SNPs/variants
showed LATS1 expression (Figure 2). On the other hand, the uri-
nary bladder cancerous tissues (UC1, 11, and 15) that shared
SNPs at 16045, 34614, 41736, and 56177, appear to have similar
LATS1-gene-expression-profile alteration (Figure 2). The results
suggested that these combined SNPs likely contribute to the dis-
ruption of LATS1 RNA steady state levels. On the other hand,
the urinary bladder cancer tissue (UC13) that encompass four
SNPs/variants at 16045, 35366, 41736, and 42029, which are
located at the 5′UTR and introns regions, showed high expres-
sion levels of the LATS1 gene compared to the urinary bladder
cancer tissue without LATS1 SNPs/variants (UC6). The urinary
bladder cancerous tissue (UC8) showed remarkably low levels
of LATS1 mRNA (Figure 2). Five SNPs/variants were reported
within the LATS1 of UC8 at position 35366, 41625, 41736, 42029,
and 56177, resulting in three SNPs/variants in the introns 4 and
6, besides a silent SNP within exon 8 and a missense variant
within exon 6 that encodes for the catalytic domain. Moreover,
we observed that the examined samples that encompass the SNP
at position 56177 within exon 8 of LATS1, which resulted in silent
mutation in the LATS1 catalytic domain, showed very low or
no LATS1 expression, including the peritumoral urinary blad-
der tissue UN3 as well as the urinary bladder cancerous tissues
UC1, UC8, UC11, and UC15. These observations emphasize the
impact of each single single-base-sequence alterations may have
on the tumor suppressor LATS1 gene expression in cancer, as well
as the contribution of these SNPs/variants in LATS1 inactivation
and the subsequent increased risk of urinary bladder and colon
malignancies.
The differential expression of the LATS1 mRNA in the uri-
nary bladder cancer tissues that shared LATS1 SNPs/variants
urged us to assess potential roles for SNPs/variants in the non-
coding regions of LATS1 on its expression. In silico analysis
of the LATS1 sequence using Transfac database revealed that
the SNPs/variants interrupt several consensus TFs binding sites
(Table 4). Such SNPs/variants may disrupt the binding of the
cognate TF. TRANSFAC identified five SNPs/variants to overlap
with predicted binding sites of various TFs. Genome Trax iden-
tified CpG_islands, which were mapped to seven SNPs/variants
at the 5′UTR (Table 4). The analysis identified SNPs/variants
that disrupted the TF recognition sequence of one TF but main-
tained the binding of another TF. For instance the SNP at 35366,
allowed Zfp105 TF binding but resulted in loss of the ardi5a
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FIGURE 3 | Schematic diagram of the Transfac predicted TF binding
sites within a fragment of LATS1 gene. (A) Transfac diagram of the wild
type (WT) fragment of LATS1 intron-1 that depicts the myogenin
transcription factor-binding site as created by the variant at consensus
position 15943. (B) Diagram of the depicted SREBP TF binding site that is
generated by the variant at 42029 (indicated by an arrow) at LATS1
intron-6 as well as the predicted TF binding sites that were interrupted by
the variant (Kel et al., 2003; Matys et al., 2006).
binding site, a TF that stimulates histone acetylation. The variant
at 15943, which is located within LATS1 intron 1, did not inter-
rupt a regulatory region. However, this mutation generated the
core sequence (CAgCTG) for the binding of Myogenin TF, which
is a TF that regulates cell cycle and stem cell proliferation and
was associated with various types of tumors including rhabdo-
myosarcoma, liver neoplasms, soft tissues neoplasms, and neu-
roectodermal tumors (Figure 3A) (Wang et al., 1995; Meyer and
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Brinck, 1997; Kumar et al., 2000; Kobayashi et al., 2004). Likewise,
a variant at intron 6, located at consensus position 42029, cre-
ated the consensus sequence for the binding of the TF SREBP
(Figure 3B). The effect of this variant could have contributed
to LATS1 over-expression observed with the urinary bladder
cancer tissue (UC13), at which the variant at 42029 was reported.
Therefore, such SNPs/variants may be the aberrant building
blocks that disrupt cellular mechanisms and contribute to the
urinary bladder and colon malignances.
We report alterations of single base pairs in the LATS1 gene, of
Egyptian patients with urinary bladder and colon cancer tissues.
Additionally, we identified novel variants within the LATS1 gene
that contributed to the down regulation of its mRNA expression
in urinary bladder tissues. LATS1 variants and its’ relationship to
ethnicity hasn’t been previously addressed. Therefore, we cannot
deduce that the novel variants identified would be different from
other racial populations. However, this study reveals the signifi-
cance of the tumor suppressor activity of LATS1 and highlights
the association of LATS1 single-base-sequence alterations with
urinary bladder and colon tumors. Nonetheless, further studies
need to be conducted with relatively larger sample size and eval-
uate the functionality of the LATS1 protein with the detected
SNPs/variants.
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